Antibody-drug conjugates (ADCs) have revolutionized the landscape of oncology by delivering targeted therapies that minimize damage to healthy cells while maximizing the impact on cancerous tissues. However, researchers and clinicians are now exploring the many therapeutic possibilities of ADCs in treating a variety of non-cancerous conditions such as autoimmune, infectious, neurological, cardiovascular, and metabolic diseases.
This month provided not just one, but two FDA approvals for antibody drugs treating patients with paroxysmal nocturnal hemoglobinuria (PNH)!
A recent editorial by researchers at Yale University School of Medicine describes how we are entering the golden age for antibody-drug conjugates (ADCs) in gynecologic cancer, which includes difficult to treat tumors such as uterine carcinosarcomas and platinum-resistant ovarian cancer.
Healthspan and lifespan research are two distinct but interconnected areas in aging studies. Lifespan research aims to extend the total number of years an individual lives, seeking interventions that can delay the onset of age-related diseases and prolong life itself. In contrast, healthspan researc
Immunostimulatory ADCs (iADCs), also known as immune-stimulating antibody conjugates (iSACs), arean advanced form of targeted cancer therapy. They not only activate innate immunity but also stimulate adaptive immunity, providing a dual therapeutic effect to eliminate tumor cells. They combine
The approval of Eli Lilly’s Kisunla (donanemab-azbt), a humanized IgG1 monoclonal antibody, is just one of the major advancements in the treatment of Alzheimer's disease (AD)! This drug is now available in the US for adults with early symptomatic AD, including those with mild cognitive impairment (MCI) and mild dementia stage of AD with amyloid pathology.
Blood disorders, including anemias, coagulopathies, leukemias, lymphomas, and thrombocytopenias, disrupt the normal functioning of blood components. Antibody therapeutics, such as monoclonal antibodies (mAbs), have transformed treatment approaches by offering targeted, high-specificity interventions.
This report aims to explore the events and trends of the biopharmaceutical industry in Q2 (April, May, June). Besides crovalimab and Vyloy, two more novel antibody drugs have been approved this year
Over four years have passed since the first SARS-CoV-2 outbreak, and scientific advancements have reshaped our understanding of immunity and virus dynamics.
Immune checkpoint blockade antibody therapy is an approach in cancer treatment that uses the body's immune system to target and destroy cancer cells. Immune checkpoints are regulatory pathways in immune cells that cancer cells exploit to evade detection. Key immune checkpoints include PD-1, PD-L1, and CTLA-4. By blocking these pathways, antibodies like pembrolizumab, nivolumab, and ipilimumab allow T-cells to recognize and attack cancer cells more effectively.
Intravenous immunoglobulins (IVIGs) offer a versatile treatment modality for a variety of immune-mediated disorders. Originally used for antibody replacement therapy, their unexpected anti-inflammatory and immunomodulatory effects have allowed them to extend their use to
Antibody drugs in ophthalmology represent a significant advancement in treating various eye diseases. These biologics target specific proteins involved in pathological processes, such as vascular endothelial growth factor (VEGF), which plays a key role in conditions like age-related macular degenera
You can also contact us on the Scientist and Science Exchange marketplaces.
